Skip to content

Establishment and Application of Pancreatic Cancer and Liver Cancer Therapeutic Effect Prediction and Drug Efficacy Evaluation System

Establishment and Application of Pancreatic Cancer and Liver Cancer Therapeutic Effect Prediction and Drug Efficacy Evaluation System

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015246
Enrollment
Unknown
Registered
2018-03-17
Start date
2018-03-21
Completion date
Unknown
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer, pancreatic cancer

Interventions

Patient derived xenograft Modeling Group:PDX???

Sponsors

The General Hospital of People’s Liberation Army(301 hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological histological diagnosis of pancreatic cancer or liver cancer patients; 2. Clinical examination without other neoplastic diseases 3. Can take surgical resection or biopsy to obtain fresh tumor tissue samples; 4. Objective tumors that meet RECIST 1.1 criteria and can be evaluated by CT/MRI; 5. KPS score = 60, expected survival time = 3 months; Comprehensive assessment of patients who can tolerate chemotherapy and targeted therapy 6. The patient voluntarily signed the informed consent form, with good compliance, willing active treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1. Unplanned reoperation after surgery; 2. During the course of treatment, the patient was found to have other tumors, or a second tumor was found, which interfered with this experimental study; 3. KPS score = 60 points or blood biochemical tests suggest that patients are not suitable for continuing chemotherapy or chemotherapy has been delayed; 4. Cannot or refuse to collect tumor samples, including tumor tissue blocks, or malignant pleural effusion and ascites; 5. Refused to receive treatment plans or follow-up plans;

Design outcomes

Primary

MeasureTime frame
Overall survival;Progressive survival;Objective response rate;

Countries

China

Contacts

Public ContactXianjie Shi

The General Hospital of People's Liberation Army

shixianjie301@126.com+86 13501376410

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026